Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial

A multicomponent vaccine has been developed to reduce the frequency of acute exacerbations of COPD associated with non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) infections, containing NTHi (PD and PE-PilA) and Mcat (UspA2) surface proteins. In a randomised, observer-bli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Philippe De Smedt, Geert Leroux-Roels, Corinne Vandermeulen, Annaelisa Tasciotti, Gennaro Di Maro, Marie Dozot, Daniela Casula, Margherita Annaratone, Daniele Riccucci, Ashwani Kumar Arora
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Acute exacerbation Antibody persistence Clinical trial COPD Haemophilus influenzae Moraxella catarrhalis Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/378e0635c1c34397a8de8fc1124c2db9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial

Ejemplares similares